GastrointestinalResearch Phase

Motilin

Intravenous

Overview

Motilin is a 22-amino acid endogenous peptide hormone secreted by enteroendocrine cells in the duodenum and jejunum. It binds to motilin receptors on gastrointestinal smooth muscle and enteric neurons, stimulating phase III migrating motor complexes and promoting gastric emptying.

Mechanism of Action

The therapeutic rationale for exogenous motilin or receptor agonists includes treatment of gastroparesis and postoperative ileus. Erythromycin acts as a motilin receptor agonist, demonstrating the clinical relevance of this pathway..

Research Summary & Key Findings

Natural motilin itself has not been developed as a therapeutic due to rapid degradation and tachyphylaxis with repeated dosing. Synthetic motilin receptor agonists such as camicinal and mitemcinal have been evaluated in phase II trials for gastroparesis, with mixed results and concerns about receptor desensitization. Current clinical use of motilin pathway stimulation relies primarily on macrolide antibiotics rather than peptide-based agents.

Clinical Status

Research Phase

Motilin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Intravenous

Related Peptides in Gastrointestinal

Find a Provider

Find a verified provider who offers Motilin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Motilin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.